Detection and Automatic Segmentation of Liver Nodules in Patients With Colorectal Adenocarcinoma

NCT ID: NCT04834596

Last Updated: 2021-04-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-02

Study Completion Date

2022-05-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the diagnostic performance of artificial intelligence-based software for the detection of liver nodules on scanner in patients at risk of liver metastases of colorectal cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to evaluate the performance of a software for liver nodule detection in patients with colorectal cancer compared to the consensus of two radiologists analysis.

300 hepatic scanners will be analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Detection of Liver Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients without hepatic metastases

hepatic scanner of 100 patients with colorectal cancer without hepatic metastases will be analysed

retrospectives analysis on hepatic scanner

Intervention Type OTHER

hepatic scanner will be analysed by two radiologist and by the software

patients with synchronous hepatic metastases

hepatic scanner of 100 patients with colorectal cancer with synchronous hepatic metastases will be analysed

retrospectives analysis on hepatic scanner

Intervention Type OTHER

hepatic scanner will be analysed by two radiologist and by the software

patients with metachronous hepatic metastases

hepatic scanner of 100 patients with colorectal cancer with metachronous hepatic metastases will be analysed

retrospectives analysis on hepatic scanner

Intervention Type OTHER

hepatic scanner will be analysed by two radiologist and by the software

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

retrospectives analysis on hepatic scanner

hepatic scanner will be analysed by two radiologist and by the software

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients consecutively treated for colorectal cancer a
* Availability of imaging by injected abdominal scanner including at least one portal phase
* Age over 18

Exclusion Criteria

* Patients with treatment of the hepatic nodule by ablation or previous hepatic surgery
* Imaging follow-up \<12 months
* Non-interpretable scanner (artefact, injection quality, etc.)
* Patients with more than 10 liver metastases
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UHAngers

Angers, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marie Bost

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

marie bost

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021 OOPS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.